Peripheral Tolerance

Peripheral tolerance is the second major arm of immunological self-restraint, operating within secondary lymphoid organs (lymph nodes, spleen, and mucosal Peyer's patches) and non-lymphoid peripheral tissues after T lymphocytes and B lymphocytes have completed their maturation and exited the thymus and bone marrow. Although central tolerance eliminates or edits the majority of high-affinity autoreactive clones during early ontogeny, thymic and marrow negative selection is intrinsically incomplete: low-to-moderate affinity self-reactive T cells routinely enter the periphery, developmental Stage-specific self-proteins (such as lactation proteins, post-pubertal germ-cell antigens, or placental factors) may be absent or under-represented in the neonatal thymus, and innocuous foreign antigens—including dietary proteins and the ~3.8 × 10¹³ commensal microbes of the human microbiome—are encountered exclusively at peripheral mucosal surfaces. Peripheral tolerance prevents autoimmune tissue destruction and chronic allergic or inflammatory pathology through five concerted mechanisms: immunological ignorance, clonal anergy, coinhibitory checkpoint signaling (CTLA-4 and PD-1), extrinsic suppression by Foxp3⁺ regulatory T cells (T_reg), and activation-induced cell death (AICD).

Bretscher-Cohn and Jenkins-Schwartz Formulation of Signal 1 vs. Signal 2

Building on Peter Bretscher and Melvin Cohn's associative recognition model (1970), Marc Jenkins and Ronald Schwartz (1987) demonstrated experimentally that productive activation of a naive CD4⁺ or CD8⁺ T lymphocyte requires the simultaneous delivery of two distinct biochemical signals at the immunological synapse by a professional antigen-presenting cell (APC):

• Signal 1 (Antigen-Specific TCR Recognition): Ligation of the αβ T-cell receptor (TCR–CD3 complex) and CD4/CD8 co-receptor by a specific peptide–major histocompatibility complex (pMHC) ligand on the APC.
• Signal 2 (Costimulatory Verification of Danger): Ligation of the constitutive T-cell costimulatory receptor CD28 by its ligands B7-1 (CD80) and B7-2 (CD86) on the APC.

As conceptualized in Charles Janeway's Pattern Recognition Theory (1989) and Polly Matzinger's Danger Model (1994), resting steady-state dendritic cells and macrophages that phagocytose healthy apoptotic self-cells in sterile tissues express negligible levels of CD80 and CD86. Only when innate pattern-recognition receptors (such as Toll-like receptors, RIG-I, or cGAS–STING) detect microbial pathogen-associated molecular patterns (PAMPs) or necrotic damage-associated molecular patterns (DAMPs) do APCs upregulate CD80/CD86 by 50- to 100-fold.

Biochemical Execution of Clonal Anergy: NFAT Without AP-1 and E3 Ubiquitin Ligases

When a mature self-reactive T cell encounters its cognate self-peptide–MHC complex (Signal 1 alone) on a quiescent, steady-state dendritic cell or a non-hematopoietic tissue parenchymal cell lacking B7-1/B7-2 (absence of Signal 2), the T cell is not merely left unstimulated; rather, it enters a durable state of functional paralysis termed clonal anergy, in which the cell cannot produce interleukin-2 (IL-2) or proliferate even if subsequently restimulated by a fully mature B7-expressing APC:

1. Unbalanced Ca²⁺/NFAT Signaling Without Ras/MAPK/AP-1: Isolated TCR signaling activates phospholipase C-γ1 (PLCγ1) to generate inositol 1,4,5-trisphosphate (IP₃), releasing endoplasmic reticulum Ca²⁺ stores and opening ORAI1 CRAC channels. Sustained intracellular Ca²⁺ activates the phosphatase calcineurin, which dephosphorylates Nuclear Factor of Activated T cells (NFAT1/NFAT2), driving its nuclear translocation. However, without CD28 costimulation to amplify Ras–ERK and PKCθ–JNK signaling, the partner transcription factor AP-1 (Fos/Jun heterodimer) is not assembled.
2. Transcriptional Induction of the Anergy Program: Whereas an NFAT:AP-1 ternary complex binds composite enhancers at the IL2, IFNG, and TNF promoters to drive effector immunity, monomeric or homodimeric NFAT (acting without AP-1) binds a distinct set of low-affinity promoters to transcribe anergy-enforcing genes, headed by the transcription factors Egr2 and Egr3, diacylglycerol kinase-α (DGKα, which consumes DAG to shut off RasGRP1), and three E3 ubiquitin ligases: Cbl-b, GRAIL (RNF128), and Itch.
3. Proteolytic Destruction of Proximal TCR Signaling Nodes: Cbl-b, GRAIL, and Itch ubiquitinate PLCγ1, PKCθ, and the TCR ζ-chain, targeting them for endolysosomal or proteasomal degradation and epigenetically silencing the IL2 locus via DNA methyltransferase DNMT3A recruitment.

Even after naive T cells are primed, peripheral tolerance relies on inducible negative-feedback receptors—termed immune checkpoints, whose characterization earned James P. Allison and Tasuku Honjo the 2018 Nobel Prize in Physiology or Medicine—to terminate responses and protect host organs from immunopathology:

CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4 / CD152)

CTLA-4 serves as the master brake on early T-cell priming inside secondary lymphoid organs. Structurally homologous to CD28, CTLA-4 binds the exact same APC ligands—CD80 (B7-1) and CD86 (B7-2)—but with 10- to 20-fold higher binding affinity and avidity (K_d ≈ 0.2–0.4 μM for CTLA-4–CD80 vs. ~4 μM for CD28–CD80). In resting naive T cells, CTLA-4 is sequestered inside intracellular clathrin-coated vesicles via interaction of its cytoplasmic YVKM motif with the AP-2 adaptor complex and chaperoned against lysosomal degradation by LRBA (Lipopolysaccharide-Responsive and Beige-Like Anchor protein). Upon TCR signaling, CTLA-4 vesicles exocytose to the central supramolecular activation cluster (cSMAC) of the immunological synapse in direct proportion to TCR signal strength.

CTLA-4 restrains T-cell activation through both cell-intrinsic and cell-extrinsic mechanisms:

1. Competitive Exclusion of CD28: By forming bivalent lattice arrays with homodimeric CD80 in the synaptic cleft, CTLA-4 competitively outcompetes CD28 for B7 binding.
2. Trans-Endocytosis (Trogocytosis) of CD80 and CD86: As demonstrated by David Sansom and Lucy Walker (2011), CTLA-4 expressed constitutively at high levels on Foxp3⁺ regulatory T cells physically rips CD80 and CD86 molecules out of the plasma membrane of opposing dendritic cells via trans-endocytosis, internalizing the B7 ligands into the T_reg cell's own lysosomes for degradation. Stripped of surface CD80/CD86, the dendritic cell is rendered incapable of delivering Signal 2 to conventional naive self-reactive T cells. Consequently, Ctla4^−/− mice die at 3 to 4 weeks of age from fulminant multiorgan lymphoproliferative myocarditis and pancreatitis, and humans with heterozygous CTLA4 haploinsufficiency or biallelic LRBA deficiency develop severe autoimmune enteropathy, cytopenias, and interstitial lung disease (treatable with soluble CTLA-4–Ig / abatacept, which replaces the missing B7-masking function).

PD-1 (Programmed Cell Death Protein 1 / CD279)

Whereas CTLA-4 acts primarily at the priming stage in lymph nodes, PD-1 acts primarily inside non-lymphoid peripheral tissues to limit effector T-cell cytotoxicity against self-parenchyma. Induced on activated CD4⁺ and CD8⁺ T cells, B cells, and myeloid cells, PD-1 binds two ligands: PD-L1 (B7-H1 / CD274)—which is broadly inducible on vascular endothelium, pancreatic β-islets, cardiomyocytes, placental syncytiotrophoblasts, and epithelial cells in response to Type I and Type II interferons (IFN-γ)—and PD-L2 (B7-DC / CD273), expressed primarily on dendritic cells and macrophages.

When PD-1 engages PD-L1 on a tissue cell, the tyrosine residues within its cytoplasmic Immunoreceptor Tyrosine-Based Inhibitory Motif (ITIM) and Immunoreceptor Tyrosine-Based Switch Motif (ITSM) are phosphorylated by Lck. The phosphorylated ITSM recruits the Src-homology-2 domain-containing protein tyrosine phosphatase SHP-2 (PTPN11) (and SHP-1), which directly dephosphorylates the cytoplasmic tail of CD28 as well as CD3ζ and ZAP-70, attenuating PI3K–Akt–mTOR metabolic reprogramming and halting granzyme/perforin degranulation and IFN-γ secretion.

Dominant, cell-extrinsic peripheral tolerance is maintained by CD4⁺CD25⁺Foxp3⁺ regulatory T cells (T_reg), which constitute 5% to 10% of peripheral CD4⁺ T cells in healthy humans and mice. Pioneered by Shimon Sakaguchi (1995), who identified CD25 as a phenotypic marker of suppressive CD4⁺ T cells, and Steven Ziegler, Mary Brunkow, Fred Ramsdell, and Alexander Rudensky (2001–2003), who established the forkhead/winged-helix transcription factor Foxp3 as the lineage-specifying master regulator mutated in Scurfy mice and human X-linked IPEX syndrome, the peripheral T_reg pool comprises two complementary developmental subsets:

1. Thymus-Derived T_reg Cells (tT_reg, ~70%–80% of systemic pool): Selected in the thymic medulla on AIRE/FEZF2-dependent self-antigens (characterized by expression of Helios / IKZF2 and Neuropilin-1 and complete epigenetic demethylation of the FOXP3 CNS2 enhancer); these cells police systemic organ-specific self-antigens.
2. Peripherally Induced T_reg Cells (pT_reg, enriched at mucosal interfaces): Generated extrathymically in the intestinal lamina propria, mesenteric lymph nodes, and maternal-fetal decidua when naive conventional CD4⁺Foxp3⁻ T cells recognize innocuous dietary antigens, commensal microbiota antigens, or paternal fetal alloantigens in the presence of transforming growth factor-beta (TGF-β), all-trans retinoic acid (produced by mucosal CD103⁺ dendritic cells via RALDH2), and colonic microbial short-chain fatty acids (especially butyrate), which inhibit histone deacetylases (HDACs) at the FOXP3 CNS1 intronic enhancer.

Foxp3⁺ T_reg cells suppress autoreactive T cells, B cells, and APCs through a multi-pronged arsenal:

• Costimulatory Stripping: Constitutive CTLA-4-mediated trans-endocytosis of CD80 and CD86 from dendritic cells.
• Cytokine Sink (IL-2 Deprivation): T_reg cells do not transcribe IL2 (repressed by Foxp3:NFAT complexes) but express maximal levels of the trimeric high-affinity IL-2 receptor (CD25/CD122/CD132), competitively scavenging local IL-2 and starving neighboring autoreactive effector T cells into Bim-dependent apoptosis.
• Immunosuppressive Cytokines: Secretion of IL-10 (essential for preventing spontaneous colitis at mucosal barriers), TGF-β (activated from latent LAP complexes via T_reg surface integrin α_vβ₈ and GARP), and the heterodimeric cytokine IL-35 (Ebi3/p35).
• Purinergic Metabolic Disruption: Co-expression of the cell-surface ectonucleotidases CD39 (ENTPD1) and CD73 (NT5E), which sequentially hydrolyze pro-inflammatory extracellular ATP → AMP → Adenosine. Extracellular adenosine binds A_2A adenosine receptors on effector T cells and dendritic cells, elevating intracellular cAMP and activating Protein Kinase A (PKA) to inhibit NF-κB and TCR signaling.

When self-reactive T or B lymphocytes are repeatedly restimulated by abundant, persistent self-antigens, peripheral tolerance eliminates them via Activation-Induced Cell Death (AICD) triggered by the death receptor Fas (CD95 / APO-1) and its homotrimeric ligand Fas Ligand (FasL / CD178). Upon engagement by FasL, the cytoplasmic Death Domain (DD) of trimerized Fas recruits the adaptor protein FADD (Fas-Associated Death Domain) and procaspase-8 (or procaspase-10) to assemble the Death-Inducing Signaling Complex (DISC). Proximity-induced dimerization activates Caspase-8, which directly cleaves executioner Caspase-3 and Caspase-7 (and cleaves the BH3-only protein Bid into tBid to amplify mitochondrial cytochrome c release), driving rapid non-inflammatory apoptosis. Mice carrying loss-of-function mutations in Fas (lpr, lymphoproliferation) or Fasl (gld, generalized lymphoproliferative disease) and humans with Autoimmune Lymphoproliferative Syndrome (ALPS) accumulate massive numbers of aberrant CD3⁺CD4⁻CD8⁻TCRαβ⁺ double-negative T cells along with lupus-like autoantibodies and autoimmune hemolytic anemia or thrombocytopenia.

Finally, specialized anatomical sites—including the anterior chamber of the eye, the central nervous system parenchyma, the seminiferous tubules of the testis, and the feto-maternal placenta—maintain immunological privilege by combining tight endothelial blood-tissue barriers and reduced MHC class Ia expression with high local concentrations of TGF-β2, vasoactive intestinal peptide (VIP), indoleamine 2,3-dioxygenase (IDO1) (which catabolizes essential tryptophan into pro-apoptotic kynurenines that starve infiltrating T cells), and constitutive parenchymal expression of FasL and PD-L1 to immediately disarm or delete any infiltrating inflammatory lymphocytes.

1. Jenkins, M. K., & Schwartz, R. H. (1987). "Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo." Journal of Experimental Medicine, 165(2), 302–319. https://doi.org/10.1084/jem.165.2.302
2. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995). "Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases." Journal of Immunology, 155(3), 1151–1164. https://doi.org/10.4049/jimmunol.155.3.1151
3. Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003). "Foxp3 programs the development and function of CD4⁺CD25⁺ regulatory T cells." Nature Immunology, 4(4), 330–336. https://doi.org/10.1038/ni904
4. Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., Hou, T. Z., Futter, C. E., Anderson, G., Walker, L. S. K., & Sansom, D. M. (2011). "Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4." Science, 332(6029), 600–603. https://doi.org/10.1126/science.1202947
5. Mueller, D. L. (2010). "Mechanisms maintaining peripheral tolerance." Nature Immunology, 11(1), 21–27. https://doi.org/10.1038/ni.1817